天美传媒

HPLC-UV Method for the Determination of Enalapril in Bulk, Pharmaceutical Formulations and Serum

Safila Naveed^1*, Najma Sultana² and M.Saeed Arayne²

¹Jinnah University for Women, Karachi, Pakistan

²United Biotechnologies, Karachi-75290, Pakistan

*Corresponding Author:

Safila Naveed
Jinnah University for Women
Karachi, Pakistan
Tel: 00923002621917
E-mail: safila117@yahoo.com, drsafila@gmail.com

Received date: December 05, 2011; Accepted date: January 17, 2012; Published date: January 20, 2012

Citation: Naveed S, Sultana N, Arayne MS (2012) HPLC-UV Method for the Determination of Enalapril in Bulk, Pharmaceutical Formulations and Serum. J Anal Bioanal Tech 3:130. doi: 10.4172/2155-9872.1000130

Copyright: © 2012 Naveed S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Analytical & Bioanalytical Techniques

Abstract

A simple reversed phase HPLC method have been successfully developed and validated for the quantitative determination of enalapril maleate (ENP) in bulk material, pharmaceutical formulation and serum. Purospher Start C 18 (250 cm x 4.6 mm, 5 μm) and Hypersil, ODS columns were used. The mobile phase, methanol-acetonitrile-water (70:30v/v pH 3.5 adjusted by phosphoric acid), was delivered at a flow rate of 1 mLmin -1 , eluent was monitored using UV detector at 215 nm. The proposed method is specific, accurate (99-102%), precise (intra-day and inter-day variation 0.07-1.25%) and linearity (R 2 >0.999) within the desired range 2.5-100 μgmL -1 concentration. The detection limit and quantification 3.9 ngmL -1 and 12 ngmL -1 respectively. The anticipated method is applicable to routine analysis of ENP in pharmaceutical formulations as well as in human serum samples.

Keywords

Enalapril maleate; HPLC; Validation

Introduction

Enalapril maleate is chemically described as (S)-1-[N-[1- (ethoxycarbonyl)-3-phenylpropyl]-L-alanyl] -L-proline, (Z)-2-butenedioate salt (Figure 1) is an ester prodrug which is hydrolyzed to pharmacologically active enalaprilate, a specific competitive inhibitor of ACE, It inhibits the active sites of a zinc glycoprotein [1]. The angiotensin converting enzyme (ACE) blocking the conversion of angiotensin I to angiotensin II, whose levels are elevated in patients with hypertension [2]. Enalaprilat, the pharmacologically active metabolite of enalapril, a widely used angiotensin converting enzyme inhibitor (ACEI), is available in intravenous injectable dosage forms, which are administered in the management of hypertension when rapid onset of action of drug is required and/or oral enalapril therapy is not practical. Therefore, the availability of a suitable method for determination of enalaprilat in parenteral dosage forms may be of remarkable importance in conducting the in vitro quality control tests on preparations containing this drug. Because of some physicochemical difficulties inherent to this drug mainly the lack of a well-discernible peak in the absorption spectrum of the drug [3].

Figure 1: Enalapril maleate.

The following methods have been used for the estimation of enalapril maleate in substance: HPLC [4-6], spectroscopy VIS [7], potentiometric with enantioselective membrane electrode [8], and capillary electrophoretic [9]. But these methods were not applicable to pharmaceutical formulations. Almost all previously reported methods used acetonitrile in their mobile phase which may increase the cost of the method. The main purpose of our study was to develop a simple, reliable and economical method to determine enalapril in a relatively short time with high linearity using diclofenac sodium as internal standard. Therefore, this study focused on the development of simple and rapid isocratic RP-HPLC method which can be employed for the routine analysis of enalapril in bulk drug, pharmaceutical formulations and in serum.

Experimental

Material and reagents enalapril

Standard bulk drug sample of enalapril were supplied by MERCK SHARP & DOHME (Pvt). Diclofenac sodium was obtained from Yung Shin Pharmaceutical Ind. Co. Ltd.; four different formulations of enalapril were used including Cortec 10 mg Atco Pharma (Pvt.) Ltd ,Renitec 10 mg MSD, HPLC grade acetonitrile and methanol were obtained from Merck Schuchardt OHG, Darmstadt, Germany.

Instrumentation

HPLC system equipped with Shimadzu LC-20 AT VP Pump, SPD- 20AV VP Shimadzu UV visible detectors and second HPLC system consisted of an LC-10 AT VP Shimadzu pump, SPD-10AV VP Shimadzu UV visible detector, both connected by CBM-102 communication Bus Module Shimadzu to Intel Pentium 4 machine with Shimadzu CLASS-VP software (Version 5.03) and Rheodyne manual injector fitted with a 20 μL loop. Separation was achieved on a Purospher Start C₁₈ (250 cm x 4.6 mm, 5 μm) column and Hypersil, ODS (25 cm x 4.6 mm, 5 μm). The chromatographic analysis was integrated using a Mobile phase, which was methanol-acetonitrile-water (85:5:10, v/v/v pH 2.75 adjusted by phosphoric acid). The mobile phase was sonicated by DGU-14 AM on-line degasser, and filtered through 0.45-micron membrane filter, calibrated Pyrex glassware was used for the solution and mobile phase preparation.

Preparation of solutions

To produce a concentration of 100 μgmL⁻¹, 10 mg of the enalapril and internal standard were diluted to 100 mL with mobile phase. This solution was used for preparation of working solutions which were prepared by diluting the stock solutions with the same solvent to contain 2.5-100 μgmL⁻¹ for enalapril and for IS then filtered with 0.45-micron membrane filter. These solutions were ready to inject.

Analysis of formulation

Twenty tablets of four different brands were accurately weighed, grinded to make a fine powder. Calculated quantity of powder of each brand was weighed, which was corresponding to 10 mg of enalapril and shifted to separate 100 mL volumetric flask. Each was dissolved in the mobile phase and filtered through a membrane filter (0.45 μ). The sample solutions were further diluted to desired concentrations and then used for the analysis.

Procedure for human serum

Plasma sample, obtained from healthy volunteers, was collected and stored at -20°C. Then, 1.0mL of frozen plasma mixed with 10 mL of acetonitrile. The mixture was vortexed for one minute and then centrifuged for 10 minutes at 10,000 rpm. It was then alienated supernatant by filtration (0.45 μ pore size membrane filter). An aliquot serum sample was fortified with enalapril to get final concentrations of 100, 20, 25,10,5 and 2.5 μgmL⁻¹.

Results and Discussion

Method development and optimization

To select the optimal chromatographic conditions, different C₁₈ stationary phases have been tried. Best separation, adequate resolution short retention time and symmetric peak of ENP and Internal Standard were achieved by two difference columns which were Purospher STAR RP-and Hypersil, ODS. To investigate appropriate wavelength for determination of ENP and IS, we scanned solution of both drugs by UV-visible spectrophotometer. It was observed that the maximum absorbance of drug was obtained at 215 nm. Diclofenac sodium was used as an internal standard, retention time of enalapril was found to be 2.4 min and that of internal standard was 4.0 minutes respectively.

Initially methanol and water were tried in the ratio of 80:20 (v/v), as a result, ENP and IS did not separate properly, so the above mobile phase was varied as 90:10 (v/v), both drugs separated but the peak was not symmetrical. When mobile phase (methanol-water, 70:30 v/v) both drugs showed typical peak nature and symmetry. To select the optimum mobile phase pH range 2.5 to 4.0 were investigated, excellent performance was achieved at pH 3.5 adjusted with phosphoric acid. Total run time was 5 min; short analysis times are essential for routine analysis.

Method validation

The developed method was validated by various parameters which include system suitability, selectivity, specificity, accuracy test, linearity, precision, robustness, ruggedness, sensitivity, limit of detection and quantification, according to US Pharmacopeia and ICH guidelines

System suitability

The HPLC system was equilibrated with the initial mobile phase composition, followed by 6 injections of the same standard. These 6 consecutive injections were used to evaluate the system suitability on each day of method validation. Parameter of system suitability are peaks symmetry (symmetry factor), theoretical plates of the column, mass distribution ratio (capacity factor), and resolution as summarized in Table 1.

Table 1: System suitability parameters.

Specificity and selectivity

In order to determine the specificity of the method in presence of pharmacopoeial impurities, no peak of excepients was found in chromatogram, which proved that the method can be applied successfully to dosage formulation and method demonstrated good resolutions. Specificity was also determined by screening sample of human serum, which was free from interfering endogenous plasma components (Figure 2). Figure 3 represents typical chromatograms of drug and internal standard in serum.

Figure 2: Representative chromatogram of enalapril and internal standard in formulations.

Figure 3: Representative chromatogram of enalapril and internal standard in serum.

Linearity

Linearity was determined in the range 2.5-100 μg mL⁻¹. Concentration of ENP versus peak area was subjected to least square linear regression analysis. A linear regression line was obtained with correlation coefficient (R² > 0.999). The regression equations for active and serum (Figure 3) were display in Table 2.

Table 2: Regression statistics.

Accuracy

Method accuracy was evaluated as the percentage of recovery of known amounts of ENP to the pharmaceutical formulation and serum. It is performed at spike concentration that was 80%, 100% and 120%. Each sample was injected five times and result range was 98.9-102.5%, compiled in Table 3, high recovery indicated that the method has a high degree of accuracy.

Table 3: Accuracy of enalapril.

Precision

Precision of the proposed method was determined by repeatability (intra-day precision) and intermediate precision (inter-day precision). It was expressed as relative standard deviation (RSD). Six different concentrations of ENP in the linear range were analyzed in the same day (intra-day precision) and two consecutive days (inter-day precision); every sample was injected five times. Both intra- and inter-day RSD values were in the range 0.07-1.25% confirming good precision (Table 4). The results were insignificant and indicated no remarkable deference in interday and intraday precision.

Table 4: Precision of ENP.

Limit of detection and limit of quantification

The limits of detection (LOD) (was calculated by lowest concentration of ENP) and quantification (LOQ) were determined from the calibration curve. The LOD and LOQ were 3.9ngmL^-1 and 12ngmL^-1 respectively.

Robustness

Robustness was performed by making minor changes in the percentage of mobile phase (methanol or water) wave length, pH and flow rate. Therefore, five repeated samples were injected under small varia- tions of each parameter. When a parameter was changed ± 0.2 % (in flow rate), ± 0.2% (pH 3.5), and ± 5 % wave length from its optimum condition, the shifting in retention time of ± 0.2% was observed that assessed as inconsequentiality. The method proved to be quite stable (Table 5).

Table 5: Robustness of the method (n=6).

Ruggedness

Ruggedness of our method was determined in two different labs. Lab 1 was Research Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi while other lab was lab 9, Department of Chemistry, Faculty of science, University of Karachi. Two different instruments one was LC 10 and LC 20. Two different columns Purospher STAR C₁₈ and Hypersil, ODS were used. All parameters were compared the developed method did not show any remarkable difference in calculated results from acceptable limits in precision, but the area under curve of peak was affected with change of wavelength.

Conclusion

A simple and reliable HPLC method for determining in bulk, human serum and pharmaceutical dosage formulation has been successfully developed. The limit of quantification, small sample volume and short chromatographic time of this method are particularly adapted for routine assay. The intra-run and inter-run variability and accuracy results were in acceptable limit according to ICH guidelines. The short analysis time (< 5min) enables its application in routine and quality control analysis of finished products.

References

1. Sweetman SC (2005) Martindale: The Complete Drug Reference. Pharmaceutical press, London & Chicago 34: 900-901.
2. Dominic P Ip, Gerald S, Brenner (1987)
3. Hosnieh T , Mehrdad H (2001)
4. H. Trabelsi, Bouabdallah S, Sabbah F, Raouafi K, Bouzouita K (2000)
5. Yu C, Zhang H, Hong YC, Chen GL, Zhang Yaowu SM, Fenxi Z (1996) 16: 389-391.
6. Oklobdzija M, Kuftinec J, Hohnjec M, Kajfez F (1988)
7. Stanisz B (1999)
8. Prasad CVN, Saha RN, Parimoo P (1999)
9. Hillaert S, W van den Bossche (2000)